Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States
In patients with RA treated with a first-line TNFi, most patients who did not achieve a treatment target at an initial evaluation also failed to achieve the treatment target at 12 months. Therefore, evaluating treatment as early as 3 months after initiation may help indicate future clinical improvements and could serve as a reasonable timepoint to consider changing therapy for patients with an inadequate response.
Authors
- Patrick Zueger (ORCID: https://orcid.org/0000-0002-3412-9895)
- Christina Charles‐Schoeman (ORCID: https://orcid.org/0000-0002-1768-7019)
- Manish Jain (ORCID: https://orcid.org/0000-0002-7263-9829)
- E. Mcdearmon-Blondell
- Yi Peng (ORCID: https://orcid.org/0000-0003-1593-8336)
- John Tesser (ORCID: https://orcid.org/0000-0002-2706-7171)
- Siran Fang (ORCID: https://orcid.org/0000-0001-9135-4063)
- Oishi Tanjinatus
Institutions
- University of California, Los Angeles (US)
- Captain James A. Lovell Federal Health Care Center (US)
- AbbVie (United States) (US)
- Arthritis and Rheumatism Associates (US)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1007/s40744-025-00808-z
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00